» Articles » PMID: 16969100

Proliferation: the Most Prominent Predictor of Clinical Outcome in Breast Cancer

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2006 Sep 14
PMID 16969100
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

We recently identified a gene expression cassette of 97 unique genes that were consistently differentially expressed between low and high grade breast carcinomas. The majority of these genes were overexpressed in high grade tumors and, as expected, they were associated with cell cycle progression and proliferation. Interestingly, by applying this gene expression cassette to several datasets, we demonstrated that intermediate grade tumors were composed of a mixture of well- and poorly- differentiated tumors with statistically distinct clinical outcome similar to those of low and high grade carcinomas. Furthermore, these proliferation-related genes appear to be a common denominator of several existing prognostic gene expression signatures. This recapitulates their prognostic power far beyond the estrogen receptor (ER) status and highlights the importance of proliferation genes in breast cancer biology. Importantly, their weight seems to be far more important in ER-positive than in ER-negative disease.

Citing Articles

Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer.

Witkiewicz A, Wang J, Schultz E, OConnor T, OConnor T, Levine E Oncogene. 2025; .

PMID: 40011574 DOI: 10.1038/s41388-025-03308-0.


Determinants of response to CDK4/6 inhibitors in the real-world setting.

Witkiewicz A, Schultz E, Wang J, Hamilton D, Levine E, OConnor T NPJ Precis Oncol. 2023; 7(1):90.

PMID: 37704753 PMC: 10499925. DOI: 10.1038/s41698-023-00438-0.


RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models.

Kumarasamy V, Nambiar R, Wang J, Rosenheck H, Witkiewicz A, Knudsen E Oncogene. 2022; 41(27):3524-3538.

PMID: 35676324 PMC: 10680093. DOI: 10.1038/s41388-022-02362-2.


Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer.

Loibl S, Furlanetto J Breast. 2021; 62 Suppl 1:S70-S79.

PMID: 34930649 PMC: 9097805. DOI: 10.1016/j.breast.2021.12.008.


A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans.

Ibrahim A, Bilsland A, Rickelt S, Morris J, Stein T Breast Cancer Res. 2021; 23(1):90.

PMID: 34565423 PMC: 8474794. DOI: 10.1186/s13058-021-01470-3.